Zentalis Pharmaceuticals, Inc.
ZNTL
$4.15
-$0.01-0.12%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -35.35M | -35.22M | -26.69M | -26.87M | -48.28M |
| Total Depreciation and Amortization | 151.00K | 157.00K | 160.00K | 160.00K | 262.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.97M | 5.50M | 738.00K | 334.00K | 13.63M |
| Change in Net Operating Assets | -728.00K | -1.38M | -1.17M | -8.33M | 1.75M |
| Cash from Operations | -32.96M | -30.94M | -26.96M | -34.71M | -32.64M |
| Capital Expenditure | -34.00K | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | 129.00K | 0.00 | 564.00K | 5.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.05M | 32.32M | 28.32M | 29.81M | 40.47M |
| Cash from Investing | 30.01M | 32.45M | 28.32M | 30.38M | 40.48M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 331.00K | 5.39M | 115.00K | 0.00 | 189.00K |
| Repurchase of Common Stock | -1.45M | -9.98M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -1.12M | -4.59M | 115.00K | 0.00 | 189.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.07M | -3.08M | 1.47M | -4.33M | 8.03M |